Vital Venture Capital
Venture capitalSimsbury Β· Series AβGrowth
Investment thesis
Vital Venture Capital pursues investments in businesses where its principals maintain deep operational knowledge and established networks. The firm targets growth-stage companies with existing revenues across B2B SaaS, medical devices, and diagnostics. Investments are structured to provide downside protection through preferred capital positions and underlying asset value, with independent board governance. The firm prioritizes management teams aligned through equity incentives, sustainable competitive advantages, and target markets exceeding $100 million. Early-stage opportunities are evaluated on management strength and exceptional potential, while later-stage investments require referenceable customers, recurring revenue models, and demonstrated competitive moats.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 3 of 18 portfolio companiesAI & Machine Learning Γ2Biotech Γ2Deep Tech Γ2Cybersecurity Γ1Defense Tech Γ1EdTech Γ1Healthtech Γ1Semiconductors Γ1
HQs:United StatesΓ2
Investments Β· 18 tracked
founders shown can be your intro pathCircadence develops gamified, cloud-based cybersecurity training and awareness platforms for individuals, teams, and government agencies. The company creates high-fidelity virtual simulations and cyber ranges aligned with NIST/NICE frameworks for hands-on learning.
AI & Machine LearningCybersecurityDefense TechEdTech
Michael J. Moniz(Co-founder, President, and CEO)Christopher T. Blisard(Co-founder and Chief Operating Officer)
Ginkgo Bioworks develops autonomous laboratory systems that automate manual benchwork in biotechnology R&D, enabling scientists to conduct experiments through natural language requests rather than manual lab work.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Jason Kelly(Founder)inReshma SohoniAustin Che(Founder)inTom Knight(Founder)in
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Frequently asked questions
- What stage does Vital Venture Capital invest at?
- Vital Venture Capital invests at the Series A, Series B, Series C, Growth stages.
- What sectors does Vital Venture Capital focus on?
- Vital Venture Capital focuses on Digital Health, Medical Devices, SaaS.
- Where is Vital Venture Capital located?
- Vital Venture Capital is headquartered in Simsbury, US.
- Does Vital Venture Capital lead rounds?
- Yes, Vital Venture Capital leads investment rounds.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Kleiner Perkins is a venture capital firm that invests across early-stage and growth companies, with a portfolio spanning multiple sectors and geographies. The firm has been active since 1972 and is known for backing transformative technology companies.
OCV Partners is a Los Angeles-based venture capital firm that invests in companies with differentiated technologies, leveraging decades of company-building experience to identify and create asymmetric advantages for portfolio companies.